Who makes AZD4635 solid oral formulation - fasted?

AZD4635 solid oral formulation - fasted is developed by AstraZeneca.

What development phase is AZD4635 solid oral formulation - fasted in?

AZD4635 solid oral formulation - fasted is in Phase 1.

Last reviewed 2026-04-23 · How we verify

AZD4635 solid oral formulation - fasted

AstraZeneca · Phase 1 active Small molecule

At a glance

Generic name	AZD4635 solid oral formulation - fasted
Sponsor	AstraZeneca
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

AZD4635 Relative Bioavailability Study (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AZD4635 solid oral formulation - fasted CI brief — competitive landscape report
AZD4635 solid oral formulation - fasted updates RSS · CI watch RSS
AstraZeneca portfolio CI